Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trial

Ibrutinib demonstrated superior response rates and survival for treatment-naïve chronic lymphocytic leukemia (CLL) patients in a pivotal study that excluded patients younger than 65 (<65) and/or with chromosome 17p13 deletion (del(17p13)). We examined outcomes and toxicities of CLL patients who w...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Am J Hematol
Main Authors: Mato, Anthony R., Roeker, Lindsey E., Allan, John N., Pagel, John M., Brander, Danielle M., Hill, Brian T., Cheson, Bruce D., Furman, Richard R., Lamanna, Nicole, Tam, Constantine S., Handunnetti, Sasanka, Jacobs, Ryan, Lansigan, Frederick, Bhavsar, Erica, Barr, Paul M., Shadman, Mazyar, Skarbnik, Alan P., Goy, Andre, Beach, Douglas F., Svoboda, Jakub, Pu, Jeffrey J., Sehgal, Alison R., Zent, Clive S., Tuncer, Hande H., Schuster, Stephen J., Pickens, Peter V., Shah, Nirav N., Rhodes, Joanna, Ujjani, Chaitra S., Nabhan, Chadi
Format: Artigo
Sprog:Inglês
Udgivet: 2018
Fag:
Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7552812/
https://ncbi.nlm.nih.gov/pubmed/30132965
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ajh.25261
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker